- $150.99bn
- $199.12bn
- $33.42bn
- 90
- 35
- 75
- 74
Annual balance sheet for Amgen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 10,647 | 8,037 | 9,305 | 10,944 | 11,973 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,324 | 5,839 | 6,392 | 7,942 | 7,501 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 21,144 | 19,385 | 22,186 | 30,332 | 29,030 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5,297 | 5,750 | 6,006 | 6,592 | 7,100 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 62,948 | 61,165 | 65,121 | 97,154 | 91,839 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11,653 | 12,184 | 15,687 | 18,392 | 23,099 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 53,539 | 54,465 | 61,460 | 90,922 | 85,962 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 9,409 | 6,700 | 3,661 | 6,232 | 5,877 |
Total Liabilities & Shareholders' Equity | 62,948 | 61,165 | 65,121 | 97,154 | 91,839 |
Total Common Shares Outstanding |